{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706240,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12376632"],"award-info":[{"award-number":["PNRR-MAD-2022-12376632"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cpcardiol.2023.102229","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T21:31:55Z","timestamp":1703626315000},"page":"102229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-6805","authenticated-orcid":false,"given":"Daniela","family":"Di Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Cadeddu Dessalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Madaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Manganaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Deidda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Paola","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102229_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12012-011-9141-z","article-title":"Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist","volume":"12","author":"Bonura","year":"2012","journal-title":"Cardiovasc Toxicol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102229_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/antiox9070641","article-title":"Redox imbalances in ageing and metabolic alterations: implications in cancer and cardiac diseases. an overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC)","volume":"9","author":"Mercurio","year":"2020","journal-title":"Antioxidants (Basel)."},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102229_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer Therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0005","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thrombo- embolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.675811","article-title":"Cardiovascular issues in tyrosine kinase inhibitors treatments for chronic myeloid leukemia: a review","volume":"12","author":"Santoro","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0007","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.cpcardiol.2023.102229_bib0008","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102229_bib0009","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102229_bib0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102229_bib0011","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2459\/JCM.0000000000001346","article-title":"Does the HFA\/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?","volume":"23","author":"Tini","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102229_bib0012","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/jcm12041278","article-title":"Heart failure association-international cardio-oncology society risk score validation in HER2-positive breast cancer","volume":"12","author":"Cronin","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102229_bib0013","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Di Lisi","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102229_bib0014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"23","key":"10.1016\/j.cpcardiol.2023.102229_bib0015","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0016","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0017","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0018","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0019","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjcard.2021.07.001","article-title":"Meta-analysis evalu- ating the use of statins to attenuate cardiotoxicity in cancer patients receiving an- thracyclines and trastuzumab-based chemotherapy","volume":"156","author":"Shahid","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131219","article-title":"Statins as preventive therapy for anthracycline cardiotoxicity: A meta-analysis of randomized controlled trials","volume":"391","author":"D'Amario","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102229_bib0022","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102229_bib0023","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0024","doi-asserted-by":"crossref","first-page":"e30515","DOI":"10.1002\/pbc.30515","article-title":"Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane","author":"Bertorello","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0025","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102229_bib0026","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102229_bib0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12916-019-1474-7","article-title":"Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study","volume":"18","author":"Freisling","year":"2020","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2023.102229_bib0028","first-page":"947","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0029","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.11.174","article-title":"Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond","volume":"227","author":"Di Lisi","year":"2017","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102229_bib0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10741-020-09926-y","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia","year":"2020","journal-title":"Heart Fail Rev"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102229_bib0031","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11912-023-01411-7","article-title":"Cardiovascular Effects of immune checkpoint inhibitors: more than just myocarditis","volume":"25","author":"Inno","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102229_bib0032","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0033","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-015-2056-5","article-title":"Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period","volume":"142","author":"Guddati","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"38","key":"10.1016\/j.cpcardiol.2023.102229_bib0034","doi-asserted-by":"crossref","first-page":"ehad191","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0035","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102229_bib0036","first-page":"865","volume":"11","author":"Gevaert","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"1150","key":"10.1016\/j.cpcardiol.2023.102229_bib0037","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220999","article-title":"Multimodality imaging in cardio-oncology: the added value of CMR and CCTA","volume":"96","author":"Lisi","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0038","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s11547-020-01280-1","article-title":"The sub-Millisievert era in CTCA: the technical basis of the new radiation dose approach","volume":"125","author":"Schicchi","year":"2020","journal-title":"Radiol Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102229_bib0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2020.10.002","article-title":"Usefulness of Stress Echocardiography in the Management of Patients Treated with Anticancer Drugs","volume":"34","author":"Novo","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0041","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcin.2018.10.026","article-title":"Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis","volume":"12","author":"Landes","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"39","key":"10.1016\/j.cpcardiol.2023.102229_bib0042","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0043","article-title":"Transcatheter aortic valve intervention in patients with cancer","volume":"12","author":"Leedy","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0044","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.amjcard.2016.05.052","article-title":"Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer","volume":"118","author":"Watanabe","year":"2016","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102229_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102229_bib0046","first-page":"35","article-title":"Sacubitril\/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data","volume":"7","author":"Frey","year":"2021","journal-title":"Cardiooncology"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102229_bib0047","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril-valsartan in cancer patients with heart failure","volume":"7","author":"Mart\u00edn-Garcia","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0048","doi-asserted-by":"crossref","unstructured":"Tajstra M, Dyrbu\u015b M, Rutkowski T, et\u00a0al. Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial. ESC Heart Fail. 2023 Jul 14. doi:10.1002\/ehf2.","DOI":"10.1002\/ehf2.14466"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102229_bib0049","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","article-title":"Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"95","author":"Chang","year":"2021","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0051","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102229_bib0052","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/ejhf.2594","article-title":"Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?","volume":"24","author":"Abdelhamid","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102229_bib0053","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaccao.2023.05.008","article-title":"Cardiac Interventions in patients with active, advanced solid and hematologic malignancies: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Leong","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2979","article-title":"State-of-the-art document on optimal contemporary management of cardiomyopathies","author":"Seferovi\u0107","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102229_bib0055","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.mayocp.2016.05.013","article-title":"Myocarditis in clinical practice","volume":"91","author":"Sinagra","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0056","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0057","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2017.1393674","article-title":"Cardio-oncology in multiple myeloma: is it time for a specific focus?","volume":"59","author":"Mancuso","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0058","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. a position statement of the european society of cardiology working group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.cpcardiol.2023.102229_bib0059","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2023.102229_bib0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"IndolfiC. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"Sabatino","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102229_bib0061","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623006461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623006461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:31:26Z","timestamp":1758940286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623006461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0146280623006461"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102229","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102229"}}